Trial Profile
A Phase 1 Study Of The Safety, Pharmacokinetics And Anti-tumor Activity Of Talazoparib, Poly (Adp-ribose) Polymerase (Parp) Inhibitor, In Japanese Patients With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Sep 2022
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary)
- Indications Advanced breast cancer; Carcinoma; Male breast cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 01 Aug 2022 Planned End Date changed from 1 Jul 2022 to 31 Aug 2024.
- 23 Jun 2021 Results (n=9) assessing safety, pharmacokinetics and preliminary efficacy of talazoparib in Japanese patients with advanced solid tumors, published in the Investigational New Drugs.
- 08 Feb 2021 Planned End Date changed from 28 Dec 2022 to 1 Jul 2022.